Peptide News Digest

#T-Cell-Engager

2 stories

Clinical Trials · View digest

Enara Bio Debuts ENA101, First-in-Class DARKFOX-Targeting Peptide T-Cell Engager at AACR

Enara Bio presented ENA101 at AACR 2026 on April 20, a first-in-class bispecific T-cell engager targeting DARKFOX — a novel cancer-specific 'dark antigen' peptide presented by HLA-A*03:01 and expressed in multiple solid tumors. Preclinical data showed low-picomolar potency and complete tumor regression in xenograft models with once-weekly dosing. IND submission planned for 2H 2026.

Research · View digest

Molecular Partners Announces Three AACR 2026 Posters Including First Switch-DARPin T-Cell Engager MP0632 Preclinical Data

Molecular Partners presents three posters at AACR 2026 announcing MP0632 as the first logic-gated Switch-DARPin T-cell engager candidate, targeting MSLN/EpCAM-expressing solid tumors. MP0632 showed tumor regression in dual-antigen preclinical models with limited activity on single-antigen tumors, supporting a favorable therapeutic window. The company also presented updated data for Radio-DARPin MP0712, currently in a US Phase 1/2a trial for DLL3-expressing tumors.